Literature DB >> 16094309

Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation.

Laurence Faivre1, Pascale Saugier-Veber, Jean-Paul Pais de Barros, Bruno Verges, Bertrand Couret, Bernard Lorcerie, Christel Thauvin, Françoise Charbonnier, Frédéric Huet, Philippe Gambert, Thierry Frebourg, Laurence Duvillard.   

Abstract

Splenomegaly with sea-blue histiocytes, thrombocytopenia and hypertriglyceridemia is a very rare association that has been described in only one report to date. The molecular defect in the two reported patients consists in a deletion of a leucine at position 149 in the receptor-binding region of the apoE molecule. Here, we report on another family in whom the proband and his brother were diagnosed with splenomegaly, thrombocytopenia and hypertriglyceridemia. An apoE p.Leu149del mutation was found in both subjects. A large beta band in the VLDL fraction and elevated VLDL cholesterol-to-plasma triglyceride ratio was observed in the proband only. Their mother, presenting with isolated hypertriglyceridemia, also carried the same p.Leu149del mutation. The coexistence of factors facilitating the development of hypertriglyceridemia and/or low HDL-cholesterol level could explain why the proband and his brother developed a splenomegaly with thrombocytopenia, whereas the mother did not. Moreover, the presence of an apoE2 allele in the proband likely explains the more severe phenotype we observed in this subject. In conclusion, the apoE p.Leu149del mutation results in a very striking phenotype including one or all symptoms among splenomegaly, thrombocytopenia and hypertriglyceridemia, and should be considered as a differential diagnosis of storage disorders in the causes of splenomegaly with sea-blue histiocytes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16094309     DOI: 10.1038/sj.ejhg.5201480

Source DB:  PubMed          Journal:  Eur J Hum Genet        ISSN: 1018-4813            Impact factor:   4.246


  6 in total

1.  Familial hypercholesterolemia in an Iranian family due to a mutation in the APOE gene (first case report).

Authors:  Shahab Noorian; Rezvan Razmandeh; Roshanak Jazayeri
Journal:  J Diabetes Metab Disord       Date:  2022-03-10

2.  APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia.

Authors:  Yara Abou Khalil; Oriane Marmontel; Jean Ferrières; François Paillard; Cécile Yelnik; Valérie Carreau; Sybil Charrière; Eric Bruckert; Antonio Gallo; Philippe Giral; Anne Philippi; Olivier Bluteau; Catherine Boileau; Marianne Abifadel; Mathilde Di-Filippo; Alain Carrié; Jean-Pierre Rabès; Mathilde Varret
Journal:  Int J Mol Sci       Date:  2022-05-21       Impact factor: 6.208

Review 3.  Exome sequencing: new insights into lipoprotein disorders.

Authors:  Sali M K Farhan; Robert A Hegele
Journal:  Curr Cardiol Rep       Date:  2014-07       Impact factor: 2.931

4.  Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.

Authors:  Marie Marduel; Khadija Ouguerram; Valérie Serre; Dominique Bonnefont-Rousselot; Alice Marques-Pinheiro; Knut Erik Berge; Martine Devillers; Gérald Luc; Jean-Michel Lecerf; Laurent Tosolini; Danièle Erlich; Gina M Peloso; Nathan Stitziel; Patrick Nitchké; Jean-Philippe Jaïs; Marianne Abifadel; Sekar Kathiresan; Trond Paul Leren; Jean-Pierre Rabès; Catherine Boileau; Mathilde Varret
Journal:  Hum Mutat       Date:  2012-10-11       Impact factor: 4.878

5.  An unusual presentation of LCAT deficiency as nephrotic syndrome with normal serum HDL-C level.

Authors:  Manish R Balwani; Vijaykumar A Ghodela; Vivek B Kute; Pankaj R Shah; Himanshu V Patel; Dinesh N Gera; Aruna Vanikar; Hargovind L Trivedi
Journal:  J Nephropharmacol       Date:  2016-01-05

6.  Analysis of apolipoprotein E genetic polymorphism in a large ethnic Hakka population in southern China.

Authors:  Zhixiong Zhong; Heming Wu; Hesen Wu; Pingsen Zhao
Journal:  Genet Mol Biol       Date:  2018-11-29       Impact factor: 1.771

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.